Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 49.7% year to date compared with the industry's 5.4% growth. The S&P 500 Index has also increased 15% in the same time frame. Glaukos, with a market capitalization of $7.1 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 3 ...